The purpose of this retrospective study is to learn about the real-world effects of the study medicine lorlatinib for the first-line treatment of Chinese adult patients who were diagnosed with ALK-positive a/mNSCLC. The participants included in this study are: * Aged 18 years or more * diagnosed with a/mNSCLC * confirmed with testing for ALK-positive * have started first-line lorlatinib treatment during the patient selection period In this study, the main objectives are to learn the patient characteristics and the real-world treatment pattern of first-line treatment of lorlatinib in China at a real-world setting.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Age at Start of Lorlatinib Treatment
Timeframe: At initiation of lorlatinib treatment between July 2022- October 2024
Smoking status (if available) at Start of Lorlatinib Treatment
Timeframe: At initiation of lorlatinib treatment between July 2022- October 2024
Histology of patients at start of Lorlatinib treatment
Timeframe: At initiation of lorlatinib treatment between July 2022- October 2024
Eastern Cooperative Oncology Group (ECOG) performance status of patients at Start of Lorlatinib Treatment
Timeframe: At initiation of lorlatinib treatment between July 2022- October 2024
Initial cancer stage at diagnosis of patients prior Start of Lorlatinib Treatment
Timeframe: At initiation of lorlatinib treatment between July 2022- October 2024
Current cancer stage at Start of Lorlatinib Treatment
Timeframe: At initiation of lorlatinib treatment between July 2022- October 2024
Brain metastases status at Start of Lorlatinib Treatment
Timeframe: At initiation of lorlatinib treatment between July 2022- October 2024
Pfizer CT.gov Call Center
Date of initial NSCLC diagnosis
Timeframe: At initiation of lorlatinib treatment between July 2022- October 2024
Date of a/mNSCLC diagnosis
Timeframe: At initiation of lorlatinib treatment between July 2022- October 2024
ALK-positive diagnosis prior to Start of Lorlatinib Treatment
Timeframe: At initiation of lorlatinib treatment between July 2022- October 2024
Gene testing method and results prior to initiation of lorlatinib treatment
Timeframe: At initiation of lorlatinib treatment between July 2022- October 2024
Date of brain metastases diagnosis prior to initiation of lorlatinib treatment
Timeframe: At initiation of lorlatinib treatment between July 2022- October 2024
Presence of comorbidities at Start of Lorlatinib Treatment
Timeframe: At initiation of lorlatinib treatment between July 2022- October 2024
Concomitant therapies at Start of Lorlatinib Treatment
Timeframe: At initiation of lorlatinib treatment between July 2022- October 2024
Date of lorlatinib initiation
Timeframe: At initiation of lorlatinib treatment between July 2022- October 2024
Initial lorlatinib dose at Start of Lorlatinib Treatment
Timeframe: At initiation of lorlatinib treatment between July 2022- October 2024
Dose adjustments when patients were prescribed with Lorlatinib Treatment
Timeframe: From the date of initiation of lorlatinib treatment to the date of treatment dose adjustments, assessed up to 50 months (where 50 months is the estimated maximum follow-up duration for this outcome).
Gender at Start of Lorlatinib Treatment
Timeframe: At initiation of lorlatinib treatment between July 2022- October 2024
Weight at Start of Lorlatinib Treatment
Timeframe: At initiation of lorlatinib treatment between July 2022- October 2024
Height at Start of Lorlatinib Treatment
Timeframe: At initiation of lorlatinib treatment between July 2022- October 2024
Body mass index (BMI) at Start of Lorlatinib Treatment
Timeframe: At initiation of lorlatinib treatment between July 2022- October 2024